Michael Miedler, MD
Infectious Disease · Lexington, KYNPI 1548261837
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Gilead accounts for 63.8% of it on its own, with 10 other manufacturers making up the rest.
Across 67 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$810
- Shionogi Inc$130
- Merck$84
- Insmed, Inc.$66
- AbbVie$46
- Viiv Healthcare Company$39
- plus $94 from 5 others
What the payments were for
- Food & beverage$1,19594%
- Education$746%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 43 | $810 |
| Shionogi Inc | 5 | $130 |
| Merck | 4 | $84 |
| Insmed, Inc. | 3 | $66 |
| AbbVie | 3 | $46 |
| Viiv Healthcare Company | 3 | $39 |
| Astellas Pharma US Inc | 2 | $25 |
| Cumberland Pharmaceuticals, Inc. | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $12 |
How this compares
$1,269 in reported general payments places this provider in the 60th percentile of 100 infectious disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 130 | $97,080 |
| ErtapenemErtapenem Sodium | 56 | $38,642 |
| MicafunginMicafungin Sodium | 34 | $11,763 |
| Cefepime Hcl | 19 | $8,510 |
| Vancomycin Hcl | 32 | $8,269 |
| CeftriaxoneCeftriaxone Sodium | 74 | $7,402 |
| Meropenem | 36 | $7,272 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 26 | $6,557 |
| Sodium Chloride0.9 % Sodium Chloride | 68 | $4,892 |
| Epinephrine | 13 | $4,414 |
| Doxycycline Hyclate | 102 | $1,277 |
| Ampicillin Trihydrate | 12 | $645 |
| Cephalexin | 29 | $538 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 25 | $338 |
| Cefdinir | 18 | $290 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Lexington
- David DoughertyLexington$145K
- Charles RoseLexington$68K
- Marty AllenLexington$40K
- Daniel RodrigueLexington$37K
- John MeekLexington$12K
- Mark DoughertyLexington$12K
- Andrea BanksLexington$11K
- Takako SchaningerLexington$8K
- Andrew AlexanderLexington$7K
- Richard GreenbergLexington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.